238 related articles for article (PubMed ID: 32399569)
21. Diagnosis and Management of Low-Grade Dysplasia in Barrett's Esophagus: Expert Review From the Clinical Practice Updates Committee of the American Gastroenterological Association.
Wani S; Rubenstein JH; Vieth M; Bergman J
Gastroenterology; 2016 Nov; 151(5):822-835. PubMed ID: 27702561
[TBL] [Abstract][Full Text] [Related]
22. Risk of progression in Barrett's esophagus based on diagnoses of general and gastrointestinal pathologists. A retrospective case-control study from Northern and Central Finland.
Huhta H; Melkko J; Kuopio T; Karttunen TJ; Helminen O
Scand J Gastroenterol; 2022 Sep; 57(9):1024-1029. PubMed ID: 35450519
[TBL] [Abstract][Full Text] [Related]
23. Barrett Esophagus Length, Nodularity, and Low-grade Dysplasia are Predictive of Progression to Esophageal Adenocarcinoma.
Solanky D; Krishnamoorthi R; Crews N; Johnson M; Wang K; Wolfsen H; Fleischer D; Ramirez FC; Katzka D; Buttar N; Iyer PG
J Clin Gastroenterol; 2019; 53(5):361-365. PubMed ID: 29608452
[TBL] [Abstract][Full Text] [Related]
24. Low-grade dysplasia diagnosis ratio and progression metrics identify variable Barrett's esophagus risk stratification proficiency in independent pathology practices.
Davison JM; Shah MB; Deitrick C; Chennat J; Fasanella KE; McGrath K
Gastrointest Endosc; 2018 Nov; 88(5):807-815.e2. PubMed ID: 29944863
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and Safety of Radiofrequency Ablation vs. Endoscopic Surveillance for Barrett's Esophagus With Low-Grade Dysplasia: Meta-Analysis of Randomized Controlled Trials.
Wang Y; Ma B; Yang S; Li W; Li P
Front Oncol; 2022; 12():801940. PubMed ID: 35296005
[TBL] [Abstract][Full Text] [Related]
26. Predictors for neoplastic progression in patients with Barrett's Esophagus: a prospective cohort study.
Sikkema M; Looman CW; Steyerberg EW; Kerkhof M; Kastelein F; van Dekken H; van Vuuren AJ; Bode WA; van der Valk H; Ouwendijk RJ; Giard R; Lesterhuis W; Heinhuis R; Klinkenberg EC; Meijer GA; ter Borg F; Arends JW; Kolkman JJ; van Baarlen J; de Vries RA; Mulder AH; van Tilburg AJ; Offerhaus GJ; ten Kate FJ; Kusters JG; Kuipers EJ; Siersema PD
Am J Gastroenterol; 2011 Jul; 106(7):1231-8. PubMed ID: 21577245
[TBL] [Abstract][Full Text] [Related]
27. Association between length of Barrett's esophagus and risk of high-grade dysplasia or adenocarcinoma in patients without dysplasia.
Anaparthy R; Gaddam S; Kanakadandi V; Alsop BR; Gupta N; Higbee AD; Wani SB; Singh M; Rastogi A; Bansal A; Cash BD; Young PE; Lieberman DA; Falk GW; Vargo JJ; Thota P; Sampliner RE; Sharma P
Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1430-6. PubMed ID: 23707463
[TBL] [Abstract][Full Text] [Related]
28. The significance of "indefinite for dysplasia" grading in Barrett metaplasia.
Younes M; Lauwers GY; Ertan A; Ergun G; Verm R; Bridges M; Woods K; Meriano F; Schmulen C; Johnson C; Barroso A; Schwartz J; McKechnie J; Lechago J
Arch Pathol Lab Med; 2011 Apr; 135(4):430-2. PubMed ID: 21466357
[TBL] [Abstract][Full Text] [Related]
29. Increasing prevalence of high-grade dysplasia and adenocarcinoma on index endoscopy in Barrett's esophagus over the past 2 decades: data from a multicenter U.S. consortium.
Desai M; Lieberman DA; Kennedy KF; Hamade N; Thota P; Parasa S; Gorrepati VS; Bansal A; Gupta N; Gaddam S; Young PE; Mathur S; Moawad FJ; Cash BD; Sampliner R; Vargo JJ; Falk GW; Sharma P
Gastrointest Endosc; 2019 Feb; 89(2):257-263.e3. PubMed ID: 30342028
[TBL] [Abstract][Full Text] [Related]
30. Influence of body mass index on the prevalence and progression of dysplasia in Barrett's esophagus: a retrospective analysis (.).
Thota PN; Arora Z; Benjamin T; Pagadala M; Lopez R; Sanaka MR
Scand J Gastroenterol; 2016 Nov; 51(11):1288-93. PubMed ID: 27460942
[TBL] [Abstract][Full Text] [Related]
31. Surveillance and follow-up strategies in patients with high-grade dysplasia in Barrett's esophagus: a Dutch population-based study.
Verbeek RE; van Oijen MG; ten Kate FJ; Vleggaar FP; Schipper ME; Casparie MK; van Baal JW; Siersema PD
Am J Gastroenterol; 2012 Apr; 107(4):534-42. PubMed ID: 22270082
[TBL] [Abstract][Full Text] [Related]
32. Persistence of nondysplastic Barrett's esophagus identifies patients at lower risk for esophageal adenocarcinoma: results from a large multicenter cohort.
Gaddam S; Singh M; Balasubramanian G; Thota P; Gupta N; Wani S; Higbee AD; Mathur SC; Horwhat JD; Rastogi A; Young PE; Cash BD; Bansal A; Vargo JJ; Falk GW; Lieberman DA; Sampliner RE; Sharma P
Gastroenterology; 2013 Sep; 145(3):548-53.e1. PubMed ID: 23714382
[TBL] [Abstract][Full Text] [Related]
33. Outcomes of Radiofrequency Ablation versus Endoscopic Surveillance for Barrett's Esophagus with Low-Grade Dysplasia: A Systematic Review and Meta-Analysis.
Klair JS; Zafar Y; Nagra N; Murali AR; Jayaraj M; Singh D; Rustagi T; Krishnamoorthi R
Dig Dis; 2021; 39(6):561-568. PubMed ID: 33503615
[TBL] [Abstract][Full Text] [Related]
34. Length of Barrett's esophagus in the presence of low-grade dysplasia, high-grade dysplasia, and adenocarcinoma.
Barrie J; Yanni F; Sherif M; Dube AK; Tamhankar AP
Surg Endosc; 2021 Aug; 35(8):4756-4762. PubMed ID: 32880012
[TBL] [Abstract][Full Text] [Related]
35. Risk of progression of Barrett's esophagus in patients with cirrhosis.
Apfel T; Lopez R; Sanaka MR; Thota PN
World J Gastroenterol; 2017 May; 23(18):3287-3294. PubMed ID: 28566888
[TBL] [Abstract][Full Text] [Related]
36. A Consensus Diagnosis Utilizing Surface KI-67 Expression as an Ancillary Marker in Low-Grade Dysplasia Helps Identify Patients at High Risk of Progression to High-Grade Dysplasia and Esophaegal Adenocarcinoma.
Lee C; Hayat U; Song K; Gravely AA; Mesa H; Peltola J; Iwamoto C; Manivel C; Bilal M; Shaheen N; Shaukat A; Hanson BJ
Dis Esophagus; 2023 Feb; 36(3):. PubMed ID: 36190180
[TBL] [Abstract][Full Text] [Related]
37. Clinical pathways and outcomes of patients with Barrett's esophagus in tertiary care settings: a prospective longitudinal cohort study in Australia, 2008-2016.
Na R; Miura K; O'Brien S; Eslick GD; Kendall BJ; Hourigan LF; Bourke M; Cox MR; Farrokhzadi L; Levert-Mignon AJ; Barbour AP; Clemons NJ; Duong CP; Lord RV; Phillips WA; Watson DI; Whiteman DC
Dis Esophagus; 2021 Aug; 34(8):. PubMed ID: 33306781
[TBL] [Abstract][Full Text] [Related]
38. Aberrant p53 expression is associated with neoplastic progression in Barrett oesophagus diagnosed as indefinite for dysplasia.
Chen X; Liu BL; Harpaz N; Zhu H; Polydorides AD; Liu Q
Histopathology; 2023 Feb; 82(3):454-465. PubMed ID: 36251540
[TBL] [Abstract][Full Text] [Related]
39. Development and Validation of a Model to Determine Risk of Progression of Barrett's Esophagus to Neoplasia.
Parasa S; Vennalaganti S; Gaddam S; Vennalaganti P; Young P; Gupta N; Thota P; Cash B; Mathur S; Sampliner R; Moawad F; Lieberman D; Bansal A; Kennedy KF; Vargo J; Falk G; Spaander M; Bruno M; Sharma P
Gastroenterology; 2018 Apr; 154(5):1282-1289.e2. PubMed ID: 29273452
[TBL] [Abstract][Full Text] [Related]
40. Barrett's esophagus with low-grade dysplasia: high rate of upstaging at Barrett's esophagus referral units suggests progression rates may be overestimated.
Tsoi EH; Mahindra P; Cameron G; Williams R; Norris R; Desmond PV; Raftopoulos S; Pavey D; Rattan A; Hourigan LF; Lee R; Bourke MJ; Sidhu N; Singh R; Chan A; Krishnamurthi S; Taylor ACF
Gastrointest Endosc; 2021 Nov; 94(5):902-908. PubMed ID: 34033852
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
